Filed: 11/14/2023ACC: 0001639101-23-000010
📋 What this filing means
BFAM PARTNERS (CAYMAN) LTD filed this quarterly 13F‑HR report disclosing 3 equity positions with a total reported market value of $21.42M. This filing provides a transparent view of the manager's long equity holdings as of the quarter end.
3
Positions
$21.42M
Total AUM (reported)
791.97K
Total Shares
Allocation by class
SPONSORED ADS$19.44M90.7%
CAP STK CL A$1.96M9.2%
*W EXP 03/15/202$19.3K0.1%
Portfolio Concentration
Top 3$21.42M100.0%
Top 3 weight
100.0%
Top 10 weight
100.0%
Voting Authority Distribution
Total shares with voting rights: 791.97K
Sole
Full voting authority
791.97K
shares
% of voting shares100.0%
Shared
Joint voting authority
0.00
shares
% of voting shares0.0%
None
No voting authority
0.00
shares
% of voting shares0.0%
Investment Discretion (by position count)
Sole3
Shared0
Other0
Dominant voting typeSole · 100.0% of voting shares
Institutional Holdings3
Rows:
ALIBABA GROUP HLDG LTD
SOLEShares226.97K
TypeSH
Market value$19.44M
90.75%
Sole
226.97K
Shared
0.00
None
0.00
ALPHABET INC
SOLEShares15K
TypeSH
Market value$1.96M
9.16%
Sole
15K
Shared
0.00
None
0.00
YS BIOPHARMA CO LTD
SOLEShares550K
TypeSH
Market value$19.3K
0.09%
Sole
550K
Shared
0.00
None
0.00
| Issuer | Class | Shares | Type | Value / Portfolio % | Voting — Sole | Shared | None |
|---|---|---|---|---|---|---|---|
ALIBABA GROUP HLDG LTDSOLE | SPONSORED ADS | 226.97K | SH | $19.44M 90.75% | 226.97K | 0.00 | 0.00 |
ALPHABET INCSOLE | CAP STK CL A | 15K | SH | $1.96M 9.16% | 15K | 0.00 | 0.00 |
YS BIOPHARMA CO LTDSOLE | *W EXP 03/15/202 | 550K | SH | $19.3K 0.09% | 550K | 0.00 | 0.00 |